

FILE 'CAPLUS' ENTERED AT 17:13:26 ON 11 JUL 2006

E EISENBERG RONIT/AU 25

L1 2 S (E3)

E RAZ TAMAR/AU 25

L2 15 S (E3)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 17:16:58 ON 11 JUL 2006

L3 9242 S (MAST (A) CELL) (S) DEGRANULATION

L4 10455 S (MAST (A) CELL) (S) DEGRANULAT?

L5 891 S L4 (S) PEPTIDE?

L6 132 S L4 (S) PEPTIDE? (S) (PREVENT? OR INHIBIT? OR SUPPRESS?)

L7 71 DUP REM L6 (61 DUPLICATES REMOVED)

L8 71 SORT L7 PY A

Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters: 859960

Minimum DB seq length: 0

Maximum DB seq length: 16

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database :

A_Geneseq_8:*

- 1: geneseqp1980s:*
- 2: geneseqp1990s:*
- 3: geneseqp2000s:*
- 4: geneseqp2001s:*
- 5: geneseqp2002s:*
- 6: geneseqp2003as:*
- 7: geneseqp2003bs:*
- 8: geneseqp2004s:*
- 9: geneseqp2005s:*
- 10: geneseqp2006s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	% Query		Match Length	DB	ID	Description
	Score	Match				
1	70	100.0	16	2	AAR87629	Aar87629 Signal pe
2	70	100.0	16	2	AAW37753	Aaw37753 Chimeric
3	70	100.0	16	2	AAW56394	Aaw56394 MEM polyp
4	70	100.0	16	2	AAW48689	Aaw48689 Signal pe
5	70	100.0	16	2	AAW53769	Aaw53769 PKR pepti
6	70	100.0	16	2	AAy13506	Aay13506 Signal se
7	70	100.0	16	3	AAy67954	Aay67954 Kaposi s
8	70	100.0	16	3	AAy55815	Aay55815 Fibroblas
9	70	100.0	16	4	AAE02979	Aae02979 Hydrophob
10	70	100.0	16	4	AAU97005	Aau97005 CCAAT enh
11	70	100.0	16	4	AAE11949	Aae11949 Membrane
12	70	100.0	16	4	AAU03154	Aau03154 Peptide K
13	70	100.0	16	4	AAy72476	Aay72476 Kaposi fi
14	70	100.0	16	5	ABg78989	Abg78989 Cell pene
15	70	100.0	16	5	AAU10399	Aau10399 Membrane
16	70	100.0	16	5	AAE15613	Aae15613 Kaposi's
17	70	100.0	16	5	AAU78349	Aau78349 Signal se
18	70	100.0	16	5	AAE26128	Aae26128 Kaposi fi
19	70	100.0	16	5	ABg75507	Abg75507 Signal-se
20	70	100.0	16	5	ABB81177	Abb81177 Signal se
21	70	100.0	16	5	AAE23686	Aae23686 Fluoresce
22	70	100.0	16	6	ABB82543	Abb82543 Signal se
23	70	100.0	16	6	ABR84444	Abr84444 K-FGF sig
24	70	100.0	16	6	AAE33897	Aae33897 Kaposi's
25	70	100.0	16	6	ABU09984	Abu09984 Kaposi's
26	70	100.0	16	7	ADC22454	Adc22454 Protein-d
27	70	100.0	16	7	ADF78064	Adf78064 Human mem
28	70	100.0	16	7	ADG28017	Adg28017 Kaposi FG
29	70	100.0	16	7	ADH76184	Adh76184 Transduct
30	70	100.0	16	7	ADK11581	Adk11581 Taxoid ca
31	70	100.0	16	7	ADL88653	Adl88653 MPS (Kapo
32	70	100.0	16	8	ADG73832	Adg73832 Peptide d
33	70	100.0	16	8	ADH58870	Adh58870 Glutathio
34	70	100.0	16	8	ADJ78875	Adj78875 N-termina
35	70	100.0	16	8	ADL14686	Adl14686 Cardiant
36	70	100.0	16	8	ADK15574	Adk15574 Membrane
37	70	100.0	16	8	ADO26466	Ado26466 Kaposi's

38	70	100.0	16	8	ADM97016	Adm97016 Botulinum
39	70	100.0	16	8	ADO25265	Ado25265 Signal se
40	70	100.0	16	8	ADP08148	Adp08148 Small int
41	70	100.0	16	8	ADP08145	Adp08145 Small int
42	70	100.0	16	8	ADQ60179	Adq60179 Human her
43	70	100.0	16	8	ADR31972	Adr31972 Heat shoc
44	70	100.0	16	8	ADR82252	Adr82252 Membrane
45	70	100.0	16	8	ADU15734	Adu15734 MUC1-PDZ
46	70	100.0	16	8	ADT61097	Adt61097 Novel int
47	70	100.0	16	8	ADU07192	Adu07192 Membrane
48	70	100.0	16	8	ADT61891	Adt61891 Human mem
49	70	100.0	16	8	ADT86673	Adt86673 Membrane
50	70	100.0	16	8	ADU67511	Adu67511 Membrane
51	70	100.0	16	8	ADU26590	Adu26590 Cell perm
52	70	100.0	16	8	AEB19669	Aeb19669 Novel gen
53	70	100.0	16	9	ADW25982	Adw25982 Membrane
54	70	100.0	16	9	ADW81340	Adw81340 Intrabody
55	70	100.0	16	9	ADW88632	Adw88632 Membrane
56	70	100.0	16	9	ADY32269	Ady32269 Novel can
57	70	100.0	16	9	ADY38682	Ady38682 Novel pro
58	70	100.0	16	9	ADZ64558	Adz64558 Kaposi's
59	70	100.0	16	9	ADZ68062	Adz68062 Kaposi's
60	70	100.0	16	9	ADZ69395	Adz69395 HSP20 tra
61	70	100.0	16	9	AEA98089	Aea98089 Signal se
62	70	100.0	16	9	AEA33043	Aea33043 Kaposi fi
63	70	100.0	16	9	AEA36361	Aea36361 Basic dom
64	70	100.0	16	9	AEB17248	Aeb17248 Human mem
65	70	100.0	16	9	AEA43032	Aea43032 Membrane
66	70	100.0	16	9	AEB28494	Aeb28494 MPS (kapo
67	70	100.0	16	9	AEC78139	Aec78139 NRIF3 der
68	70	100.0	16	9	AED02530	Aed02530 SN50 (NF-
69	70	100.0	16	9	AED51657	Aed51657 Cell perm
70	70	100.0	16	9	AED83101	Aed83101 Membrane
71	70	100.0	16	9	AEE39644	Aee39644 Signal se
72	70	100.0	16	10	AEE84512	Aee84512 Signal se
73	70	100.0	16	10	AEE91963	Aee91963 Kaposi FG
74	70	100.0	16	10	AEE48449	Aee48449 Signal se
75	70	100.0	16	10	AEF42977	Aef42977 Kaposi fi
76	70	100.0	16	10	AEF90254	Aef90254 Signal se
77	70	100.0	16	10	AEF99409	Aef99409 Hydrophob
78	63	90.0	15	2	AAW56398	Aaw56398 Preferred
79	63	90.0	15	3	AAU55819	Aay55819 Signal se
80	63	90.0	15	5	AAU78913	Aau78913 Fibroblas
81	63	90.0	15	9	ADZ68060	Adz68060 Kaposi's
82	63	90.0	16	3	AAY67268	Aay67268 Fibroblas
83	58	82.9	15	6	AAO16667	Aao16667 Human cel
84	55.5	79.3	15	4	AAU03166	Aau03166 Kaposi fi
85	46	65.7	14	4	AAE12500	Aae12500 Membrane
86	46	65.7	14	9	AEB09938	Aeb09938 Antiviral
87	39	55.7	11	4	AAE12491	Aae12491 Membrane
88	39	55.7	11	9	AEB09930	Aeb09930 Antiviral
89	39	55.7	13	4	AAE12480	Aae12480 Membrane
90	39	55.7	13	4	AAE12497	Aae12497 Membrane
91	39	55.7	13	9	AEB09919	Aeb09919 Antiviral
92	39	55.7	16	4	AAE12498	Aae12498 Membrane
93	39	55.7	16	9	AEB09936	Aeb09936 Antiviral
94	37	52.9	14	4	AAE12504	Aae12504 Membrane
95	37	52.9	14	9	AEB09942	Aeb09942 Antiviral
96	36	51.4	15	6	ABR39106	Abr39106 Human pro
97	34	48.6	10	6	AAE32592	Aae32592 West nile
98	34	48.6	10	6	AAE32518	Aae32518 West nile
99	33.5	47.9	13	5	ABG98327	Abg98327 Secreted
100	33	47.1	15	9	ADX24978	Adx24978 Human pro

ALIGNMENTS

RESULT 1

AAR87629

ID AAR87629 standard; peptide; 16 AA.

XX
 AC AAR87629;
 XX
 DT 23-JUL-1996 (first entry)
 XX
 DE Signal peptide of K-FGF.
 XX
 KW Signal peptide; K-FGF; kaposi fibroblast growth factor; FGF; inhibition;
 KW growth factor; nuclear localisation sequence; growth regulation; p50;
 KW tumour cell; transcription factor; NF-kappaB; therapy.
 XX
 OS Synthetic.
 XX
 PN W09534295-A1.
 XX
 PD 21-DEC-1995.
 XX
 PF 13-JUN-1995; 95WO-US007539.
 XX
 PR 13-JUN-1994; 94US-00258852.
 XX
 PA (UYVA-) UNIV VANDERBILT.
 XX
 PI Lin Y, Hawiger JJ;
 XX
 DR WPI; 1996-049396/05.
 XX
 PT Importing biologically active molecules ex vivo or in vivo into cells -
 PT useful in regulation of cell growth and inhibition of gene expression.
 XX
 PS Claim 5; Page 35; 47pp; English.
 XX
 CC This sequence represents the signal peptide of Kaposi fibroblast growth
 CC factor (K-FGF). This sequence is an importation competent signal peptide
 CC (SP), and is used in the methods of the invention. These methods are
 CC designed to import a biologically active molecule (BAM) into a cell
 CC (either ex vivo or in vivo). The methods comprise administering to the
 CC cell a complex comprising the BAM linked to an importation competent SP
 CC (such as this sequence), and thereby importing the BAM into the cell. The
 CC BAM-SP complex is optionally linked to a nuclear localisation sequence
 CC peptide (NLS), to achieve importation into the nucleus of a cell. This
 CC method can be used to regulate the growth of a cell, e.g. tumour cells.
 CC Also, for inhibiting the expression of a gene. Genes regulated by a
 CC transcription factor such as NF-kappaB are inhibited by a complex
 CC comprising an SP linked to an NLS of the active p50 subunit of NF-kappaB.
 CC This method imports BAM's into a cell using mechanisms naturally occurring
 CC in cells, thereby avoiding damaging the target cells. It can also be used
 CC to import molecules into large numbers of cells, including organs
 XX
 SQ Sequence 16 AA;

Query Match 100.0%; Score 70; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.0008;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AAVALLPAVLLALLAP 16
 |||||
 Db 1 AAVALLPAVLLALLAP 16

RESULT 2

AAW37753

ID AAW37753 standard; peptide; 16 AA.

XX

AC AAW37753;

XX

DT 20-JUL-1998 (first entry)

XX

DE Chimeric peptide 1.

XX

KW Chimeric peptide; signal peptide; ras gene product; mutation;

KW leukaemic cell; bone marrow cell; transduction.
 XX
 OS Synthetic.
 XX
 PN US5736394-A.
 XX
 PD 07-APR-1998.
 XX
 PF 03-MAY-1996; 96US-00642493.
 XX
 PR 03-MAY-1996; 96US-00642493.
 XX
 PA (BOST-) BOSTON BIOMEDICAL RES INST.
 XX
 PI Coleman PS, Sheldon K;
 XX
 DR WPI; 1998-239216/21.
 XX
 PT Cellular uptake of specific modified peptide(s) - useful for covalent
 PT bonding to, and inactivation of intracellular proteins.
 XX
 PS Disclosure; Col 3; 11pp; English.
 XX
 CC This amino acid sequence is of a chimeric peptide comprising a known
 CC signal peptide, and is used in the method of invention as a way of
 CC introducing a peptide into a cell. They are also useful for specifically
 CC covalently binding a peptide to a target protein in a cell and
 CC irreversibly block a binding site on the protein e.g. the peptide can be
 CC used to inactivate the ras gene product which is mutated in leukaemic
 CC cells and essential for survival, but not essential in normal bone marrow
 CC cells. It can also be used to deduce the role of different proteins in
 CC signal transduction pathways by systematically inactivating them and
 CC seeing the resultant effects
 XX
 SQ Sequence 16 AA;

Query Match 100.0%; Score 70; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.0008;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAVALLPAVLLALLAP 16
 |||||
 Db 1 AAVALLPAVLLALLAP 16

RESULT 3

AAW56394
 ID AAW56394 standard; peptide; 16 AA.
 XX
 AC AAW56394;
 XX
 DT 05-AUG-1998 (first entry)
 XX
 DE MEM polypeptide used to inhibit kappa-Ig light chain expression.
 XX
 KW SV40MEM polypeptide; signal peptide; fibroblast growth factor;
 KW SV40 large antigen; nuclear localisation signal; NLS;
 KW immunosuppressive activity; inhibition; nuclear translocation inhibitor;
 KW kappa immunoglobulin light chain expression; S. typhosa LPS;
 KW nuclear translocation; treatment; immune disorder; autoimmune disease;
 KW hypersensitivity; sepsis; prevention; septic shock; antiviral agent;
 KW tumour growth suppressor; MEM.
 XX
 OS Synthetic.
 XX
 PN WO9811907-A1.
 XX
 PD 26-MAR-1998.
 XX
 PF 15-SEP-1997; 97WO-US016217.
 XX

PR 20-SEP-1996; 96US-0026978P.
 PR 12-SEP-1997; 97US-00928958.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 PI Nadler SG, Cleaveland JS, Blake J, Haffar OK;
 XX
 DR WPI; 1998-217028/19.
 XX
 PT Nuclear translocation inhibitor polypeptides - comprising signal sequence
 PT for delivery through the cytoplasmic membrane and at least 2 nuclear
 PT localisation sequences.
 XX
 PS Example 3; Page 31; 69pp; English.
 XX
 CC The present sequence represents the MEM polypeptide, which contains the
 CC signal sequence of fibroblast growth factor. The immunosuppressive
 CC activity of this peptide was compared with that of the SV40MEM
 CC polypeptide (see AAW56391). The SV40MEM polypeptide causes approximately
 CC 75-80% inhibition of kappa immunoglobulin (Ig) light chain expression in
 CC response to S. typhosa LPS. L- and D-forms of the SV40MEM peptide are
 CC equally effective. The SV40MEM polypeptide exemplifies the nuclear
 CC translocation inhibitor polypeptide of the invention. Nuclear
 CC translocation inhibitor polypeptides comprise a signal sequence peptide
 CC capable of delivering the polypeptide through the cytoplasmic membrane
 CC into a cell, and at least 2 nuclear localisation sequences (NLSs). The
 CC polypeptides can be used to inhibit nuclear translocation of a cellular
 CC protein. In addition, since the nuclear translocation of certain cellular
 CC peptides is required for the host organism to mount an immune response,
 CC the polypeptide inhibitors are useful as immunosuppression agents. The
 CC polypeptides can therefore be used for the treatment of immune disorders
 CC including autoimmune diseases. The polypeptides can also be used for
 CC treating physical symptoms manifested by responses to allergens which can
 CC initiate a state of hypersensitivity, for the treatment of sepsis and in
 CC the prevention of septic shock, antiviral agents, tumour growth
 CC suppressors, and for transcriptionally modulating the expression of
 CC cellular genes
 XX
 SQ Sequence 16 AA;

Query Match 100.0%; Score 70; DB 2; Length 16;
 Best Local Similarity 100.0%; Pred. No. 0.0008;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AAVALLPAVLLALLAP 16
 |||||
 Db 1 AAVALLPAVLLALLAP 16